FLX Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:FLX Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013416
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FLX Bio Inc (FLX Bio) focuses on the discovery, development and commercialization of novel immuno-oncology agents. The company’s pipeline product, FLX925 is a drug targeting the FLT3 mutations which is found in patients with acute myeloid leukemia (AML). FLX925 simultaneously targets a second pathway involved in the AML cell growth, known as CDK4/6. FLX Bio is also developing a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate the cancer. The company has advanced into the clinic a dual-inhibitor drug that target FLT3 and CDK4/6 for the treatment of cancer.FLX Bio is headquartered in South San Francisco, California, the US.

FLX Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
FLX Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
FLX Bio Raises USD50 Million in Series B Financing 10
Partnerships 12
Cofactor Genomics Enters into Agreement with FLX Bio 12
Licensing Agreements 13
FLX Bio Enters Into Licensing Agreement with Amgen 13
FLX Bio Inc – Key Competitors 14
FLX Bio Inc – Key Employees 15
FLX Bio Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
May 31, 2017: FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board 17
Dec 12, 2016: FLX Bio appoints new board member 18
Apr 05, 2016: FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery 19
Product News 20
12/01/2016: FLX Bio Announces Poster Presentations at the American Society of Hematology Conference on FLX925, a Small Molecule FLT3/CDK4/6 Inhibitor 20
Clinical Trials 21
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate 21
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
FLX Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
FLX Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
FLX Bio Raises USD50 Million in Series B Financing 10
Cofactor Genomics Enters into Agreement with FLX Bio 12
FLX Bio Enters Into Licensing Agreement with Amgen 13
FLX Bio Inc, Key Competitors 14
FLX Bio Inc, Key Employees 15

★海外企業調査レポート[FLX Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Henry Schein Inc (HSIC)-医療機器分野:企業M&A・提携分析
    Summary Henry Schein, Inc. (Henry Schein) is a distributor of healthcare products and services. Its product and service portfolio consists of dental products, medical products, animal health products, software and technology and other value-added services. It offers generic and branded pharmaceutica …
  • CCL Industries Inc.:企業の戦略・SWOT・財務情報
    CCL Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary CCL Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Centric Health Corporation:企業のM&A・事業提携・投資動向
    Centric Health Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Centric Health Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Clayton Homes Inc:企業の戦略・SWOT・財務情報
    Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report Summary Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Aprecia Pharmaceuticals Company-製薬・医療分野:企業M&A・提携分析
    Summary Aprecia Pharmaceuticals Company (Aprecia) is a healthcare products provider that develops and markets various therapeutic products. The company's zipdos technology platform is used in the production of sponge-like wafer forms of existing medicines. It also offers 3D printing technology platf …
  • Southern Co (SO):石油・ガス:M&Aディール及び事業提携情報
    Summary Southern Co is a gas and electric utility holding company. It generates, distributes, markets and trades electricity and distributes gas. It uses a variety of sources for electricity generation including coal, oil and gas, nuclear and hydro. The company also distributes natural gas through t …
  • Hwange Colliery Co Ltd:企業の戦略・SWOT・財務分析
    Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Cleveland-Cliffs Inc:企業の戦略・SWOT・財務分析
    Cleveland-Cliffs Inc - Strategy, SWOT and Corporate Finance Report Summary Cleveland-Cliffs Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Michelin SCA (ML):企業の財務・戦略的SWOT分析
    Michelin SCA (ML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • VEON LTD. (VIP):企業の財務・戦略的SWOT分析
    VEON LTD. (VIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • B&G Foods, Inc.:企業の戦略・SWOT・財務情報
    B&G Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary B&G Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • University of California San Diego-製薬・医療分野:企業M&A・提携分析
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Medical Australia Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Medical Australia Ltd (Medical Australia), formerly BMDI TUTA Healthcare Pty Ltd is a medical device company that offers sterile and non-sterile medical plastics; wall suction, medical gas and suction pump products. The company's suction pumps include a range of mobile, portable and manual s …
  • Prognomix Inc:企業の製品パイプライン分析
    Summary Prognomix Inc (Prognomix) is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company’s products include PGX IR01, PGx GR01, PGx CD01, PGx IR02 …
  • Proximus plc (PROX):企業の財務・戦略的SWOT分析
    Proximus plc (PROX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Tenth Avenue Petroleum Corp (TPC):石油・ガス:M&Aディール及び事業提携情報
    Summary Tenth Avenue Petroleum Corp (TPC), formerly Jadela Oil Corp is an oil and gas company that explores and develops petroleum and natural gas properties in Western Canada. The company explores and develops Eagle Ford Shale in Eagle Pass of Maverick County, Texas. It operates an oilfield water d …
  • Fubon Bank (Hong Kong) Ltd:企業の戦略的SWOT分析
    Fubon Bank (Hong Kong) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • R1 RCM Inc (RCM):企業の財務・戦略的SWOT分析
    R1 RCM Inc (RCM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • NextGen Healthcare Inc (NXGN):企業の財務・戦略的SWOT分析
    NextGen Healthcare Inc (NXGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • MOIL Limited:企業の戦略・SWOT・財務情報
    MOIL Limited - Strategy, SWOT and Corporate Finance Report Summary MOIL Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆